Clinical Trial Site

Birmingham B21 9RY

3 studies enrolling now · 13 studies all time

What they study most

ANCA-Associated Vasculitis, Genetic Disease, High Cardiovascular Risk, High Risk Cardiovascular Disease, Hypertension, Kidney Diseases, Primary Hyperoxaluria Type 1 (PH1), Primary Hyperoxaluria Type 2 (PH2), Primary Hyperoxaluria Type 3 (PH3), Transthyretin Amyloidosis (ATTR) With Cardiomyopathy, Transthyretin Amyloidosis With Cardiomyopathy, Urologic Diseases

Studies at this site

• TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy — Recruiting now
• Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease — Recruiting now
• APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy) — Completed
• Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) — Completed
• A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy — Enrolling by invitation
• A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis — Running, not enrolling
• HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy — Running, not enrolling
• Long Term Extension Study in Patients With Primary Hyperoxaluria — Running, not enrolling
• A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis — Completed
• A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1 — Completed
• A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2 — Completed
• Efficacy and Safety Study of WTX101 (ALXN1840) in Adult Wilson Disease Patients — Completed
• The Assessment of Copper Parameters in Wilson Disease Participants on Standard of Care Treatment — Completed